Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency.

Coignard-Biehler H, Mahlaoui N, Pilmis B, Barlogis V, Brosselin P, De Vergnes N, Debré M, Malphettes M, Frange P, Catherinot E, Pellier I, Durieu I, Perlat A, Royer B, Le Quellec A, Jeziorski E, Fischer A, Lortholary O; CEREDIH French PID study group, Aaron L, Adoue D, Aguilar C, Aladjidi N, Alcais A, Amoura Z, Arlet P, Armari-Alla C, Bader-Meunier B, Bayart S, Bertrand Y, Bienvenu B, Blanche S, Bodet D, Bonnotte B, Borie R, Boutard P, Briandet C, Brion JP, Brouard J, Cohen-Beaussant S, Costes L, Couderc LJ, Cougoul P, Courteille V, de Saint Basile G, Devoldere C, Deville A, Donadieu J, Dore E, Dulieu F, Edan C, Entz-Werle N, Fieschi C, Forestier A, Fouyssac F, Gajdos V, Galicier L, Gandemer V, Gardembas M, Gaud C, Guillerm G, Hachulla E, Hamidou M, Hermine O, Hoarau C, Humbert S, Jaccard A, Jacquot S, Jais JP, Jaussaud R, Jeandel PY, Kebaili K, Korganow AS, Lambotte O, Lanternier F, Larroche C, Lascaux AS, Le Moigne E, Le Moing V, Lebranchu Y, Lecuit M, Lefevre G, Lemal R, Te VLT, Marie-Cardine A, Silva NM, Masseau A, Massot C, Mazingue F, Merlin E, Michel G, Millot F, Monlibert B, Monpoux F, Moshous D, Mouthon L, Munzer M, Neven B, Nove-Josserand R, Oksenhendler E, Ouachée-Chardin M, Oudot C, Pagnier A, Pasquali JL, Pasquet M, Perel Y, Picard C, Piguet C, Plantaz D, Provot J, Quartier P, Rieux-Laucat F, Roblot P, Roger PM, Rohrlich PS, Rubie H, Salle V, Sarrot-Reynauld F, Servettaz A, Stephan JL, Schleinitz N, Suarez F, Swiader L, Taque S, Thomas C, Tournilhac O, Thumerelle C, Tron F, Vannier JP, Viallard JF.

J Clin Immunol. 2019 Aug 10. doi: 10.1007/s10875-019-00658-9. [Epub ahead of print]

PMID:
31401750
2.

Lower respiratory tract amyloidosis: presentation, survival and prognostic factors. A multicenter consecutive case series.

Rech JS, Arnulf B, de Margerie-Mellon C, Talbot A, Malphettes M, Vignon M, Royer B, Lavergne D, Kambouchner M, Meignin V, Bergeron A, Prevot G, Brillet PY, Martinod E, Bridoux F, Nunes H, Jaccard A, Valeyre D, Uzunhan Y.

Am J Hematol. 2019 Aug 8. doi: 10.1002/ajh.25608. [Epub ahead of print]

PMID:
31396978
3.

CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin.

Galaine J, Turco C, Vauchy C, Royer B, Mercier-Letondal P, Queiroz L, Loyon R, Mouget V, Boidot R, Laheurte C, Lakkis Z, Jary M, Adotévi O, Borg C, Godet Y.

Int J Cancer. 2019 Aug 9. doi: 10.1002/ijc.32620. [Epub ahead of print]

PMID:
31396953
4.

New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?

Danieau G, Morice S, Rédini F, Verrecchia F, Royer BB.

Int J Mol Sci. 2019 Jul 31;20(15). pii: E3751. doi: 10.3390/ijms20153751. Review.

5.

Diagnostic score of cardiac involvement in AL amyloidosis.

Nicol M, Baudet M, Brun S, Harel S, Royer B, Vignon M, Lairez O, Lavergne D, Jaccard A, Attias D, Macron L, Gayat E, Cohen-Solal A, Arnulf B, Logeart D.

Eur Heart J Cardiovasc Imaging. 2019 Jul 10. pii: jez180. doi: 10.1093/ehjci/jez180. [Epub ahead of print]

PMID:
31292624
6.

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial.

Boyle EM, Leleu X, Petillon MO, Karlin L, Doyen C, Demarquette H, Royer B, Macro M, Moreau P, Fostier K, Marie-Lorraine C, Zarnitsky C, Perrot A, Herbaux C, Poulain S, Manier S, Beauvais D, Walker BA, Wardell CP, Vincent L, Frenzel L, Caillon H, Susanna S, Dejoie T, Avet-Loiseau H, Mohty M, Facon T; IFM2014-04 investigators.

Br J Haematol. 2019 Jun 19. doi: 10.1111/bjh.16059. [Epub ahead of print]

PMID:
31218679
7.

Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.

Perrot A, Lauwers-Cances V, Tournay E, Hulin C, Chretien ML, Royer B, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Fontan J, Voillat L, Demarquette H, Collet P, Rodon P, Sohn C, Lifermann F, Orsini-Piocelle F, Richez V, Mohty M, Macro M, Minvielle S, Moreau P, Leleu X, Facon T, Attal M, Avet-Loiseau H, Corre J.

J Clin Oncol. 2019 Jul 1;37(19):1657-1665. doi: 10.1200/JCO.18.00776. Epub 2019 May 15.

PMID:
31091136
8.

A multicentre validation study for the EU-TIRADS using histological diagnosis as a gold standard.

Trimboli P, Ngu R, Royer B, Giovanella L, Bigorgne C, Simo R, Carroll P, Russ G.

Clin Endocrinol (Oxf). 2019 Aug;91(2):340-347. doi: 10.1111/cen.13997. Epub 2019 May 3.

PMID:
31002419
9.

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Pertesi M, Vallée M, Wei X, Revuelta MV, Galia P, Demangel D, Oliver J, Foll M, Chen S, Perrial E, Garderet L, Corre J, Leleu X, Boyle EM, Decaux O, Rodon P, Kolb B, Slama B, Mineur P, Voog E, Le Bris C, Fontan J, Maigre M, Beaumont M, Azais I, Sobol H, Vignon M, Royer B, Perrot A, Fuzibet JG, Dorvaux V, Anglaret B, Cony-Makhoul P, Berthou C, Desquesnes F, Pegourie B, Leyvraz S, Mosser L, Frenkiel N, Augeul-Meunier K, Leduc I, Leyronnas C, Voillat L, Casassus P, Mathiot C, Cheron N, Paubelle E, Moreau P, Bignon YJ, Joly B, Bourquard P, Caillot D, Naman H, Rigaudeau S, Marit G, Macro M, Lambrecht I, Cliquennois M, Vincent L, Helias P, Avet-Loiseau H, Moreno V, Reis RM, Varkonyi J, Kruszewski M, Vangsted AJ, Jurczyszyn A, Zaucha JM, Sainz J, Krawczyk-Kulis M, Wątek M, Pelosini M, Iskierka-Jażdżewska E, Grząśko N, Martinez-Lopez J, Jerez A, Campa D, Buda G, Lesueur F, Dudziński M, García-Sanz R, Nagler A, Rymko M, Jamroziak K, Butrym A, Canzian F, Obazee O, Nilsson B, Klein RJ, Lipkin SM, McKay JD, Dumontet C.

Leukemia. 2019 Apr 9. doi: 10.1038/s41375-019-0452-6. [Epub ahead of print] No abstract available.

PMID:
30967618
10.

[Multiple myeloma treatment].

Talbot A, Royer B, Roussel M.

Rev Prat. 2018 Sep;68(7):787-791. French.

PMID:
30869334
11.

Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.

Pegourie B, Karlin L, Benboubker L, Orsini-Piocelle F, Tiab M, Auger-Quittet S, Rodon P, Royer B, Leleu X, Bareau B, Cliquennois M, Fuzibet JG, Voog E, Belhadj-Merzoug K, Decaux O, Rey P, Slama B, Leyronnas C, Zarnitsky C, Boyle E, Bosson JL, Pernod G; IFM Group.

Am J Hematol. 2019 Jun;94(6):635-640. doi: 10.1002/ajh.25459. Epub 2019 Apr 1.

PMID:
30859608
12.

Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study.

Jouinot A, Royer B, Chatelut E, Moeung S, Assié G, Thomas-Schoemann A, Bertherat J, Goldwasser F, Blanchet B.

Endocr Connect. 2018 Dec 1;7(12):1409-1414. doi: 10.1530/EC-18-0428.

13.

Qubit parity measurement by parametric driving in circuit QED.

Royer B, Puri S, Blais A.

Sci Adv. 2018 Nov 30;4(11):eaau1695. doi: 10.1126/sciadv.aau1695. eCollection 2018 Nov.

14.

Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment.

Vrecko S, Guenat D, Mercier-Letondal P, Faucheu H, Dosset M, Royer B, Galaine J, Boidot R, Kim S, Jary M, Adotévi O, Borg C, Godet Y.

Oncotarget. 2018 Oct 23;9(83):35394-35407. doi: 10.18632/oncotarget.26247. eCollection 2018 Oct 23.

15.

The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments.

Benbrahim O, Viallard JF, Choquet S, Royer B, Bauduer F, Decaux O, Crave JC, Fardini Y, Clerson P, Lévy V.

Hematology. 2019 Dec;24(1):173-182. doi: 10.1080/10245332.2018.1538001. Epub 2018 Nov 20.

PMID:
30458690
16.

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.

Garderet L, Kuhnowski F, Berge B, Roussel M, Escoffre-Barbe M, Lafon I, Facon T, Leleu X, Karlin L, Perrot A, Moreau P, Marit G, Stoppa AM, Royer B, Chaleteix C, Tiab M, Araujo C, Lenain P, Macro M, Voog E, Benboubker L, Allangba O, Jourdan E, Orsini-Piocelle F, Brechignac S, Eveillard JR, Belhadj K, Wetterwald M, Pegourie B, Jaccard A, Eisenmann JC, Glaisner S, Mohty M, Hulin C, Loiseau HA, Mathiot C, Attal M.

Blood. 2018 Dec 13;132(24):2555-2563. doi: 10.1182/blood-2018-07-863829. Epub 2018 Oct 3.

PMID:
30282798
17.

Coexisting cutaneous macroglobulinosis and scleredema of Buschke in a patient with a Waldenström Macroglobulinemia.

Roupie AL, Battistella M, Talbot A, Jachiet M, Bouaziz JD, Vignon-Pennamen MD, Royer B, Fermand JP, Arnulf B, Harel S.

J Eur Acad Dermatol Venereol. 2019 Mar;33(3):e104-e106. doi: 10.1111/jdv.15268. Epub 2019 Feb 28. No abstract available.

PMID:
30267590
18.

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, Dejoie T, Maheo S, Stoppa AM, Pegourie B, Karlin L, Garderet L, Arnulf B, Doyen C, Meuleman N, Royer B, Eveillard JR, Benboubker L, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Kolb B, Fohrer C, Mohty M, Macro M, Richardson PG, Carlton V, Moorhead M, Willis T, Faham M, Anderson KC, Harousseau JL, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H, Munshi N.

Blood. 2018 Dec 6;132(23):2456-2464. doi: 10.1182/blood-2018-06-858613. Epub 2018 Sep 24.

PMID:
30249784
19.

Fast and Unconditional All-Microwave Reset of a Superconducting Qubit.

Magnard P, Kurpiers P, Royer B, Walter T, Besse JC, Gasparinetti S, Pechal M, Heinsoo J, Storz S, Blais A, Wallraff A.

Phys Rev Lett. 2018 Aug 10;121(6):060502. doi: 10.1103/PhysRevLett.121.060502.

PMID:
30141638
20.

Deterministic quantum state transfer and remote entanglement using microwave photons.

Kurpiers P, Magnard P, Walter T, Royer B, Pechal M, Heinsoo J, Salathé Y, Akin A, Storz S, Besse JC, Gasparinetti S, Blais A, Wallraff A.

Nature. 2018 Jun;558(7709):264-267. doi: 10.1038/s41586-018-0195-y. Epub 2018 Jun 13.

PMID:
29899478
21.

Itinerant Microwave Photon Detector.

Royer B, Grimsmo AL, Choquette-Poitevin A, Blais A.

Phys Rev Lett. 2018 May 18;120(20):203602. doi: 10.1103/PhysRevLett.120.203602.

PMID:
29864351
22.

TIRADS score is of limited clinical value for risk stratification of indeterminate cytological results.

Chaigneau E, Russ G, Royer B, Bigorgne C, Bienvenu-Perrard M, Rouxel A, Leenhardt L, Belin L, Buffet C.

Eur J Endocrinol. 2018 Jul;179(1):13-20. doi: 10.1530/EJE-18-0078. Epub 2018 Apr 27.

PMID:
29703794
23.

A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency.

Benbrahim O, Viallard JF, Choquet S, Royer B, Bauduer F, Decaux O, Crave JC, Fardini Y, Clerson P, Lévy V.

Eur J Haematol. 2018 Jul;101(1):48-56. doi: 10.1111/ejh.13078. Epub 2018 May 17.

PMID:
29644723
24.

Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.

Feugier P, Aurran T, Mahé B, Letestu R, Nguyen-Khac F, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Cymbalista F, Ross-Weil D, Leprêtre S.

Haematologica. 2018 Jul;103(7):e304-e306. doi: 10.3324/haematol.2017.183350. Epub 2018 Mar 15. No abstract available.

25.

[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].

Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny AS, Masskouri F, Boyer JC, Etienne-Grimaldi MC.

Bull Cancer. 2018 Apr;105(4):397-407. doi: 10.1016/j.bulcan.2018.02.001. Epub 2018 Feb 24. Review. French.

26.

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

Fouquet G, Karlin L, Macro M, Caillot D, Roussel M, Arnulf B, Pegourie B, Petillon MO, Mathiot C, Hulin C, Kolb B, Stoppa AM, Brechiniac S, Rodon P, Dib M, Tiab M, Richez V, Araujo C, Wetterwald M, Garderet L, Royer B, Perrot A, Benboubker L, Decaux O, Escoffre-Barbe M, Fermand JP, Moreau P, Avet-Loiseau H, Attal M, Facon T, Leleu X.

Ann Hematol. 2018 May;97(5):831-837. doi: 10.1007/s00277-018-3236-6. Epub 2018 Jan 12.

PMID:
29330561
27.

Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial.

Bridoux F, Carron PL, Pegourie B, Alamartine E, Augeul-Meunier K, Karras A, Joly B, Peraldi MN, Arnulf B, Vigneau C, Lamy T, Wynckel A, Kolb B, Royer B, Rabot N, Benboubker L, Combe C, Jaccard A, Moulin B, Knebelmann B, Chevret S, Fermand JP; MYRE Study Group.

JAMA. 2017 Dec 5;318(21):2099-2110. doi: 10.1001/jama.2017.17924.

28.

Chemically Modified Polyvinyl Chloride for Removal of Thionine Dye (Lauth's Violet).

Ali HMAMMS, Silva CV, Royer B, Rodrigues Filho G, Cerqueira DA, Assunção RMN.

Materials (Basel). 2017 Nov 12;10(11). pii: E1298. doi: 10.3390/ma10111298.

29.

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing.

Etienne-Grimaldi MC, Le Guellec CB, Boyer JC, Chatelut E, Evrard A, Loriot MA, Paci A, Royer B, Thomas F, Ciccolini J.

Semin Oncol. 2017 Apr;44(2):159-160. doi: 10.1053/j.seminoncol.2017.06.001. Epub 2017 Jul 4. No abstract available.

PMID:
28923215
30.

Continuum of hepatitis C care in France: A 20-year cohort study.

Hermetet C, Dubois F, Gaudy-Graffin C, Bacq Y, Royer B, Gaborit C, D'Alteroche L, Desenclos JC, Roingeard P, Grammatico-Guillon L.

PLoS One. 2017 Aug 29;12(8):e0183232. doi: 10.1371/journal.pone.0183232. eCollection 2017.

31.

Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.

Fouquet G, Snell KI, Guidez S, Schraen S, Boyle E, Renaud L, Desmier D, Machet A, Moya N, Systchenko T, Gruchet C, Decaux O, Arnulf B, Fohrer C, Richez V, Kolb B, Macro M, Karlin L, Royer B, Pegourie B, Hebraud B, Caillot D, Perrot A, Moreau P, Facon T, Avet-Loiseau H, Dejoie T, Hulin C, Harding S, Leleu X.

Leuk Lymphoma. 2018 Mar;59(3):583-589. doi: 10.1080/10428194.2017.1339876. Epub 2017 Jul 12.

PMID:
28697637
32.

A simple and fast LC-MS/MS method with a very high sensitivity for the measurement of raltitrexed in human plasma.

Kim S, Bisch A, Montange D, Paillard MJ, Nguyen T, Jary M, Jacquin M, Winkfield B, Borg C, Royer B.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Aug 15;1060:240-246. doi: 10.1016/j.jchromb.2017.06.021. Epub 2017 Jun 13.

PMID:
28628839
33.

Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma.

Thiery-Vuillemin A, Orillard E, Mouillet G, Calcagno F, Devillard N, Bouchet S, Royer B.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1273-1276. doi: 10.1007/s00280-017-3320-y. Epub 2017 Apr 27.

PMID:
28451830
34.

Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease.

Assouan D, Lebon D, Charbonnier A, Royer B, Marolleau JP, Gruson B.

Br J Haematol. 2018 Jun;181(5):687-689. doi: 10.1111/bjh.14679. Epub 2017 Apr 25. No abstract available.

PMID:
28444730
35.

A new anti-mesothelin antibody targets selectively the membrane-associated form.

Asgarov K, Balland J, Tirole C, Bouard A, Mougey V, Ramos D, Barroso A, Zangiacomi V, Jary M, Kim S, Gonzalez-Pajuelo M, Royer B, de Haard H, Clark A, Wijdenes J, Borg C.

MAbs. 2017 Apr;9(3):567-577. doi: 10.1080/19420862.2017.1288770.

36.

[Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].

Weber E, Moulis G, Mahévas M, Guy C, Lioger B, Durieu I, Hunault M, Ramanantsoa M, Royer B, Default A, Pérault-Pochat MC, Moachon L, Bernard N, Bardy G, Jonville-Bera AP, Geniaux H, Godeau B, Cathébras P.

Rev Med Interne. 2017 Mar;38(3):167-175. doi: 10.1016/j.revmed.2016.09.016. Epub 2016 Oct 25. French.

PMID:
27793553
37.

A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study).

Michel M, Terriou L, Roudot-Thoraval F, Hamidou M, Ebbo M, Le Guenno G, Galicier L, Audia S, Royer B, Morin AS, Marie Michot J, Jaccard A, Frenzel L, Khellaf M, Godeau B.

Am J Hematol. 2017 Jan;92(1):23-27. doi: 10.1002/ajh.24570. Epub 2016 Nov 10.

38.

Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients.

Vignon M, Javaugue V, Alexander MP, El-Karoui K, Karras A, Roos-Weil D, Royer B, Asli B, Knebelmann B, Touchard G, Jaccard A, Arnulf B, Bridoux F, Leung N, Fermand JP.

Leukemia. 2017 Jan;31(1):123-129. doi: 10.1038/leu.2016.195. Epub 2016 Jul 20.

PMID:
27435002
39.

Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia.

Mahévas M, Gerfaud-Valentin M, Moulis G, Terriou L, Audia S, Guenin S, Le Guenno G, Salles G, Lambotte O, Limal N, Viallard JF, Cheze S, Tomowiak C, Royer B, Neel A, Debouverie O, Hot A, Durieu I, Perlat A, Cliquennois M, Deteix C, Michel M, Godeau B.

Blood. 2016 Sep 22;128(12):1625-30. doi: 10.1182/blood-2016-03-704734. Epub 2016 Jun 27.

40.

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.

Hulin C, Belch A, Shustik C, Petrucci MT, Dührsen U, Lu J, Song K, Rodon P, Pégourié B, Garderet L, Hunter H, Azais I, Eek R, Gisslinger H, Macro M, Dakhil S, Goncalves C, LeBlanc R, Romeril K, Royer B, Doyen C, Leleu X, Offner F, Leupin N, Houck V, Chen G, Ervin-Haynes A, Dimopoulos MA, Facon T.

J Clin Oncol. 2016 Oct 20;34(30):3609-3617. doi: 10.1200/JCO.2016.66.7295.

PMID:
27325857
41.

Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity.

Beziaud L, Mansi L, Ravel P, Marie-Joseph EL, Laheurte C, Rangan L, Bonnefoy F, Pallandre JR, Boullerot L, Gamonet C, Vrecko S, Queiroz L, Maurina T, Mouillet G, Hon TN, Curtit E, Royer B, Gaugler B, Bayry J, Tartour E, Thiery-Vuillemin A, Pivot X, Borg C, Godet Y, Adotévi O.

Cancer Res. 2016 Jul 15;76(14):4100-12. doi: 10.1158/0008-5472.CAN-15-2452. Epub 2016 May 17.

42.

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP.

J Clin Oncol. 2016 Jun 20;34(18):2125-32. doi: 10.1200/JCO.2015.63.1929. Epub 2016 Apr 25.

PMID:
27114594
43.

An unusual cutaneous of B-cell chronic lymphocytic leukemia presenting as a massive left-sided body ecchymosis.

Bekel L, Dhaille F, Chaby G, Sevestre H, Royer B, Defossez-Tribout C, Lombart F, Dadban A, Lok C.

JAAD Case Rep. 2015 Feb 5;1(2):49-50. doi: 10.1016/j.jdcr.2014.12.001. eCollection 2015 Mar. No abstract available.

44.

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.

Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, Garderet L, Royer B, Brechignac S, Tiab M, Puyade M, Escoffre M, Stoppa AM, Facon T, Pegourie B, Chaoui D, Jaccard A, Slama B, Marit G, Laribi K, Godmer P, Luycx O, Eisenmann JC, Allangba O, Dib M, Araujo C, Fontan J, Belhadj K, Wetterwald M, Dorvaux V, Fermand JP, Rodon P, Kolb B, Glaisner S, Malfuson JV, Lenain P, Biron L, Planche L, Caillon H, Avet-Loiseau H, Dejoie T, Attal M.

Blood. 2016 May 26;127(21):2569-74. doi: 10.1182/blood-2016-01-693580. Epub 2016 Mar 21.

45.

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.

Fouquet G, Pegourie B, Macro M, Petillon MO, Karlin L, Caillot D, Roussel M, Arnulf B, Mathiot C, Marit G, Kolb B, Stoppa AM, Brechiniac S, Richez V, Rodon P, Banos A, Wetterwald M, Garderet L, Royer B, Hulin C, Benbouker L, Decaux O, Escoffre-Barbe M, Fermand JP, Attal M, Avet-Loiseau H, Moreau P, Facon T, Leleu X; IFM (Intergroupe Francophone du Myélome).

Ann Oncol. 2016 May;27(5):902-7. doi: 10.1093/annonc/mdw017. Epub 2016 Jan 19.

46.

Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression.

Ory B, Baud'huin M, Verrecchia F, Royer BB, Quillard T, Amiaud J, Battaglia S, Heymann D, Redini F, Lamoureux F.

Clin Cancer Res. 2016 May 15;22(10):2520-33. doi: 10.1158/1078-0432.CCR-15-1925. Epub 2015 Dec 28.

47.

Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study.

Loschi M, Porcher R, Barraco F, Terriou L, Mohty M, de Guibert S, Mahe B, Lemal R, Dumas PY, Etienne G, Jardin F, Royer B, Bordessoule D, Rohrlich PS, Fornecker LM, Salanoubat C, Maury S, Cahn JY, Vincent L, Sene T, Rigaudeau S, Nguyen S, Lepretre AC, Mary JY, Corront B, Socie G, Peffault de Latour R.

Am J Hematol. 2016 Jun;91(4):366-70. doi: 10.1002/ajh.24278.

48.

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

Chretien ML, Corre J, Lauwers-Cances V, Magrangeas F, Cleynen A, Yon E, Hulin C, Leleu X, Orsini-Piocelle F, Blade JS, Sohn C, Karlin L, Delbrel X, Hebraud B, Roussel M, Marit G, Garderet L, Mohty M, Rodon P, Voillat L, Royer B, Jaccard A, Belhadj K, Fontan J, Caillot D, Stoppa AM, Attal M, Facon T, Moreau P, Minvielle S, Avet-Loiseau H.

Blood. 2015 Dec 17;126(25):2713-9. doi: 10.1182/blood-2015-06-650242. Epub 2015 Oct 29.

49.

Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.

Cohen C, Royer B, Javaugue V, Szalat R, El Karoui K, Caulier A, Knebelmann B, Jaccard A, Chevret S, Touchard G, Fermand JP, Arnulf B, Bridoux F.

Kidney Int. 2015 Nov;88(5):1135-43. doi: 10.1038/ki.2015.201. Epub 2015 Jul 15.

PMID:
26176826
50.

Factors involved in CLL pathogenesis and cell survival are disrupted by differentiation of CLL B-cells into antibody-secreting cells.

Ghamlouch H, Darwiche W, Hodroge A, Ouled-Haddou H, Dupont S, Singh AR, Guignant C, Trudel S, Royer B, Gubler B, Marolleau JP.

Oncotarget. 2015 Jul 30;6(21):18484-503.

Supplemental Content

Support Center